Angeliq regulatory Post-Marketing Surveillance (PMS) is to get data about safety and
efficacy in real practice for the indication approved by Korea Food and Drug Administration
(KFDA). This is non-interventional , prospective, multi-center study. Target number of
patients is 4500.